ArticleOncology letters2022

Androgen receptor axis-targeted agents are not superior to conventional hormonal therapy for treatment of metastatic prostate cancer.

Akinori Wada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.